Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Natera’s genomic jargon isn’t easy. Each 10-K details everything from cfDNA assay accuracy to payer reimbursement disputes, while 8-K updates often cover fast-moving clinical-trial milestones. If you’ve ever wondered how to locate test-volume data, or needed Natera insider trading Form 4 transactions before the market reacts, you know the challenge.
Stock Titan solves it. Our AI reads every Natera quarterly earnings report 10-Q filing, highlights revenue per test, and translates accounting footnotes into plain language. Real-time alerts flag Natera Form 4 insider transactions real-time, so you can track executive stock moves the moment they hit EDGAR. Need the full picture? We link each 10-K, 10-Q, 8-K, proxy DEF 14A, and S-8 in one place—Natera SEC filings explained simply. Common questions such as “How do I find the latest Natera proxy statement executive compensation?” or “Where is the Natera 8-K material events explained?” are answered inside every filing card.
Our platform doesn’t stop at document delivery. AI-powered summaries spotlight what matters for a diagnostics company: R&D spend versus cash on hand, progress of the Signatera oncology pipeline, and changes in CMS reimbursement that can swing margins. Use cases include:
- Compare quarter-over-quarter test volumes without sifting through tables
- Monitor Natera executive stock transactions Form 4 for buying or selling trends
- Assess dilution risk by reviewing shelf registrations and ATM offerings
- Download an Natera annual report 10-K simplified PDF automatically annotated by AI
- Receive instant alerts when a new Natera earnings report filing analysis is available
- Get guidance on understanding Natera SEC documents with AI-generated glossaries
Whether you’re a healthcare analyst, portfolio manager, or clinician-investor, Stock Titan turns Natera’s dense disclosures into actionable insight—no genetics PhD required.
Insider sales by a Natera director under pre-established plans — Sheena Jonathan, a director and co-founder of Natera, reported multiple sales of NTRA common stock executed under Rule 10b5-1 trading plans. On 09/17/2025 she sold 2,814 shares at a weighted average of $175.8835 and 256 shares at $176.6094, leaving 239,182 shares directly owned. On 09/19/2025 additional sales were reported including 3,444 shares and several smaller lots sold on behalf of two trusts, with reported weighted average prices in the $178.51 to $180.69 ranges. The filings state the trust-held shares are disclaimed as beneficial ownership by the reporting person.
Natera, Inc. (NTRA) insider Matthew Rabinowitz reported sales totaling 50,000 shares of common stock on September 18-19, 2025. The dispositions were effected under two separate Rule 10b5-1 trading plans adopted on June 13, 2025 and March 14, 2025, with reported weighted-average prices in ranges around $180.00–$181.40 per share. After these transactions the reporting person directly beneficially owned 2,320,852 shares and indirectly beneficially owned 15,000 shares through a spouse. No derivative securities were reported. The Form 4 was signed by an attorney-in-fact on September 19, 2025.
Natera, Inc. (NTRA) Form 144 notice reports a proposed sale of 25,527 common shares valued at $4,591,286.22 to be sold on 09/19/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The shares were acquired on 08/08/2024 through previously exercised stock options and paid in cash. The filer discloses multiple recent sales over the past three months, including 10b5-1 program sales: 14,473 shares by Matthew Rabinowitz on 09/18/2025 (gross proceeds $2,607,069.25) and several sales by related trust entities totaling 31,718 shares with combined proceeds reported. The filer certifies no undisclosed material adverse information and notes reliance on Rule 10b5-1 sales where indicated.
Natera, Inc. insider sale notice for common stock. The filer reports a proposed sale of 22,000 common shares through Charles Schwab & Co., with an aggregate market value of $4,237,900 and approximately 137,248,106 shares outstanding, representing about 0.016% of outstanding stock. The shares were originally acquired as founders' shares on 04/30/2012 from the issuer. The form also discloses five prior sales by the same person in July–September 2025 totaling 15,210 shares and gross proceeds shown for each trade. The filer attests no undisclosed material adverse information and includes standard Rule 144 representations.
Natera, Inc. (NTRA) notice reports a proposed sale of 10,000 common shares through Morgan Stanley Smith Barney with an aggregate market value of $1,800,000. The filing lists 137,248,106 shares outstanding, so the block represents about 0.0073% of outstanding stock, indicating a very small ownership fraction being sold. The shares were acquired as a gift on 03/02/2020 from the issuer, and the filing discloses two recent sales in the past three months: 5,000 shares sold on 09/12/2025 for $852,707 and 1,718 shares sold on 07/28/2025 for $240,190.65. The filer certifies they are not aware of any undisclosed material adverse information.
Natera, Inc. (NTRA) Form 144 notice reports a proposed sale of 14,473 common shares through Morgan Stanley Smith Barney on 09/18/2025 with an aggregate market value of $2,538,998.39. The filer acquired these shares on 08/08/2024 by exercising stock options and paid cash for the 14,473 shares. The filing shows recent sales by related parties: 5,000 shares sold on 09/12/2025 for $852,707.35 and 1,718 shares sold on 07/28/2025 for $240,190.66. Outstanding shares are listed as 137,248,106, which provides context for the relative size of the proposed sale.
Natera insider reported a minor disposition of common stock via charitable contribution. Solomon Moshkevich, listed as President, Clinical Diagnostics and an officer of Natera, executed a gift of 300 shares of Natera common stock on 09/15/2025, recorded as a disposition at $0 per share. After the reported transaction he beneficially owns 120,559 shares directly. The Form 4 was signed by an attorney-in-fact on 09/17/2025 and notes the sale was a charitable contribution.
Natera, Inc. (NTRA) Form 144 filed to report a proposed sale of 9,210 shares of common stock through Charles Schwab & Co., Inc., with an aggregate market value reported as $1,620,445.00 and an approximate sale date of 09/17/2025 on NASDAQ. The filer indicates the shares were acquired on 04/12/2021 from the issuer by various methods and dates. The filing also discloses multiple prior small sales by the same person during the past three months: sales on 07/02/2025, 07/16/2025, 08/08/2025, and 08/11/2025 totaling reported gross proceeds shown per sale.
Matthew Rabinowitz, Executive Chairman and Director of Natera, Inc. (NTRA), reported sales of common stock under a pre-established trading plan. On 09/12/2025 the filing shows a total of 5,000 shares sold (4,500 and 500 shares) at prices reported as a weighted average of $170.3083 for one block and $172.64 for the other, with the larger block sold at prices ranging from $170.00 to $170.93. The Form states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2025.
The filing lists 2,360,852 shares beneficially owned directly following the reported transactions. It also records indirect holdings attributed to a spouse of 25,500 and 25,000 shares on separate lines. The Form 4 was signed by an attorney-in-fact on 09/16/2025.
Natera, Inc. (NTRA) director and CEO Steven Leonard Chapman reported sales of 5,079 shares of Natera common stock on 09/02/2025 executed under a Rule 10b5-1 trading plan. The sales are reported on three lines with weighted-average prices disclosed in ranges: $164.93–$165.7750, $165.97–$166.90, and $167.41–$168.28. After these transactions Mr. Chapman beneficially owned 158,514 shares. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person and discloses that the trades were made pursuant to a plan adopted December 11, 2023 and amended December 2, 2024.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
